Earnings call transcript: Biogen beats Q3 2026 estimates as growth portfolio expands By Investing.com

Biogen reported a third-quarter 2026 earnings beat, posting adjusted earnings of $2.62 per share on revenue of $2.8 billion, ahead of analysts’ expectations of $2.02 and $2.64 billion. In premarket trading, the stock was up 1.13% to $255.59, near its 52-week high of $257.01, as investors weighed the strong results alongside rising costs and acquisition-related charges. The company said revenue rose 11% year over year, boosted by the Apellis acquisition and stronger sales from its growth portfolio. Management raised the lower end of its full-year 2026 non-GAAP EPS guidance to $12.20–$13.00. Biogen also said its growth portfolio now represents about 63% of core pharmaceutical revenue.